Stoke Therapeutics has finished enrolling the pivotal Dravet study and has turned the equity into a waiting room for a blinded test of a disease-modification claim. The June close of the EMPEROR primary cohort, with no treatment discontinuations reported through late July, is the operating event that matters this year. Open-label extensions still show multi-year seizure and Vineland gains, but those data remain unblinded and cannot substitute for the sham-controlled readout scheduled for late next year.
The tension sits in the cash account, not the clinic. Quarter-end cash and securities of $354 million would have left a thinner cushion against a doubled research budget. A subsequent at-the-market sale to a single buyer restored the pro forma pile to $420 million and preserved the early-launch runway story. Collaboration revenue from Biogen and Acadia is now a trickle after last year's license recognition, so the operating loss is the true run-rate. Launch-prep spending in the sales line is already rising before any approved product exists.
Whether the Food and Drug Administration aligns on a rolling application this winter, and whether EMPEROR then reproduces both the seizure cut and the cognition signal, is the entire forward debate. A seizure-only win still supports a commercial franchise in North America. A miss on the primary endpoint leaves a Phase 1 eye program and a platform that the current enterprise value does not treat as the main asset.